{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"19.5","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"The criteria for PR based on the Blade are shown below.\n\nPR requires 1. or all of the others:\n\n1. Some, but not all, of the criteria for CR are fulfilled\n2. ≥50% reduction in the level of the serum monoclonal paraprotein, maintained for a minimum of 6 weeks\n3. Reduction in 24 h urinary light chain excretion either by ≥90% or to \\<200 mg, maintained for a minimum of 6 weeks\n4. For patients with non-secretory myeloma only, ≥50% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy\n5. ≥50% reduction in the size of soft tissue plasmacytomas\n6. No increase in size or number of lytic bone lesions","dispersionType":"95% Confidence Interval","groups":[{"description":"SyB L-0501: The administration of SyB L-0501 at 90 mg/m\\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.","id":"OG000","title":"SyB L-0501"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to around 44 weeks","title":"Response Rate (CR+PR) Based on the Blade Criteria","type":"SECONDARY","unitOfMeasure":"percentage of paticipants"}